In vitro exposure systems and dosimetry assessment tools for inhaled tobacco products: Workshop proceedings, conclusions and paths forward for in vitro model use

Holger Behrsing, Erin Hill, Hans Raabe, Raymond Tice, Suzanne Fitzpatrick, Robert Devlin, Kent E Pinkerton, Günter Oberdörster, Chris Wright, Roman Wieczorek, Michaela Aufderheide, Sandro Steiner, Tobias Krebs, Bahman Asgharian, Richard Corley, Michael Oldham, Jason Adamson, Xiang Li, Irfan Rahman, Sonia GregoPei Hsuan Chu, Shaun McCullough, Rodger Curren

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In 2009, the passing of the Family Smoking Prevention and Tobacco Control Act facilitated the establishment of the FDA Center for Tobacco Products (CTP), and gave it regulatory authority over the marketing, manufacture and distribution of tobacco products, including those termed 'modified risk'. On 4-6 April 2016, the Institute for In Vitro Sciences, Inc. (IIVS) convened a workshop conference entitled, In Vitro Exposure Systems and Dosimetry Assessment Tools for Inhaled Tobacco Products, to bring together stakeholders representing regulatory agencies, academia and industry to address the research priorities articulated by the FDA CTP. Specific topics were covered to assess the status of current in vitro smoke and aerosol/vapour exposure systems, as well as the various approaches and challenges to quantifying the complex exposures in in vitro pulmonary models developed for evaluating adverse pulmonary events resulting from tobacco product exposures. The four core topics covered were: a) Tobacco Smoke and ECigarette Aerosols; b) Air-Liquid Interface-In Vitro Exposure Systems; c) Dosimetry Approaches for Particles and Vapours/In Vitro Dosimetry Determinations; and d) Exposure Microenvironment/Physiology of Cells. The 2.5-day workshop included presentations from 20 expert speakers, poster sessions, networking discussions, and breakout sessions which identified key findings and provided recommendations to advance these technologies. Here, we will report on the proceedings, recommendations, and outcome of the April 2016 technical workshop, including paths forward for developing and validating non-animal test methods for tobacco product smoke and next generation tobacco product aerosol/vapour exposures. With the recent FDA publication of the final deeming rule for the governance of tobacco products, there is an unprecedented necessity to evaluate a very large number of tobacco-based products and ingredients. The questionable relevance, high cost, and ethical considerations for the use of in vivo testing methods highlight the necessity of robust in vitro approaches to elucidate tobacco-based exposures and how they may lead to pulmonary diseases that contribute to lung exposure-induced mortality worldwide.

Original languageEnglish (US)
Pages (from-to)117-158
Number of pages42
JournalATLA Alternatives to Laboratory Animals
Volume45
Issue number3
StatePublished - Jul 1 2017

Fingerprint

Tobacco Products
Dosimetry
Education
Tobacco
Aerosols
Smoke
Vapors
Lung
Pulmonary diseases
Cellular Microenvironment
In Vitro Techniques
Cell Physiological Phenomena
Posters
Physiology
Marketing
Lung Diseases
Publications
Industry
Smoking
Air

Keywords

  • Computational fluid dynamics
  • COPD
  • Dosimetry
  • E-cigarette exposure systems
  • Ex vivo lung models
  • In vitro
  • In vitro lung
  • In vitro models
  • Non-animal alternatives
  • Pulmonary models
  • Reconstructed epithelium airway models
  • Tobacco exposure systems
  • Tobacco regulatory science

ASJC Scopus subject areas

  • Medicine(all)
  • Toxicology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medical Laboratory Technology

Cite this

In vitro exposure systems and dosimetry assessment tools for inhaled tobacco products : Workshop proceedings, conclusions and paths forward for in vitro model use. / Behrsing, Holger; Hill, Erin; Raabe, Hans; Tice, Raymond; Fitzpatrick, Suzanne; Devlin, Robert; Pinkerton, Kent E; Oberdörster, Günter; Wright, Chris; Wieczorek, Roman; Aufderheide, Michaela; Steiner, Sandro; Krebs, Tobias; Asgharian, Bahman; Corley, Richard; Oldham, Michael; Adamson, Jason; Li, Xiang; Rahman, Irfan; Grego, Sonia; Chu, Pei Hsuan; McCullough, Shaun; Curren, Rodger.

In: ATLA Alternatives to Laboratory Animals, Vol. 45, No. 3, 01.07.2017, p. 117-158.

Research output: Contribution to journalArticle

Behrsing, H, Hill, E, Raabe, H, Tice, R, Fitzpatrick, S, Devlin, R, Pinkerton, KE, Oberdörster, G, Wright, C, Wieczorek, R, Aufderheide, M, Steiner, S, Krebs, T, Asgharian, B, Corley, R, Oldham, M, Adamson, J, Li, X, Rahman, I, Grego, S, Chu, PH, McCullough, S & Curren, R 2017, 'In vitro exposure systems and dosimetry assessment tools for inhaled tobacco products: Workshop proceedings, conclusions and paths forward for in vitro model use', ATLA Alternatives to Laboratory Animals, vol. 45, no. 3, pp. 117-158.
Behrsing, Holger ; Hill, Erin ; Raabe, Hans ; Tice, Raymond ; Fitzpatrick, Suzanne ; Devlin, Robert ; Pinkerton, Kent E ; Oberdörster, Günter ; Wright, Chris ; Wieczorek, Roman ; Aufderheide, Michaela ; Steiner, Sandro ; Krebs, Tobias ; Asgharian, Bahman ; Corley, Richard ; Oldham, Michael ; Adamson, Jason ; Li, Xiang ; Rahman, Irfan ; Grego, Sonia ; Chu, Pei Hsuan ; McCullough, Shaun ; Curren, Rodger. / In vitro exposure systems and dosimetry assessment tools for inhaled tobacco products : Workshop proceedings, conclusions and paths forward for in vitro model use. In: ATLA Alternatives to Laboratory Animals. 2017 ; Vol. 45, No. 3. pp. 117-158.
@article{1161b79ac79641ecad4e2700e77f5268,
title = "In vitro exposure systems and dosimetry assessment tools for inhaled tobacco products: Workshop proceedings, conclusions and paths forward for in vitro model use",
abstract = "In 2009, the passing of the Family Smoking Prevention and Tobacco Control Act facilitated the establishment of the FDA Center for Tobacco Products (CTP), and gave it regulatory authority over the marketing, manufacture and distribution of tobacco products, including those termed 'modified risk'. On 4-6 April 2016, the Institute for In Vitro Sciences, Inc. (IIVS) convened a workshop conference entitled, In Vitro Exposure Systems and Dosimetry Assessment Tools for Inhaled Tobacco Products, to bring together stakeholders representing regulatory agencies, academia and industry to address the research priorities articulated by the FDA CTP. Specific topics were covered to assess the status of current in vitro smoke and aerosol/vapour exposure systems, as well as the various approaches and challenges to quantifying the complex exposures in in vitro pulmonary models developed for evaluating adverse pulmonary events resulting from tobacco product exposures. The four core topics covered were: a) Tobacco Smoke and ECigarette Aerosols; b) Air-Liquid Interface-In Vitro Exposure Systems; c) Dosimetry Approaches for Particles and Vapours/In Vitro Dosimetry Determinations; and d) Exposure Microenvironment/Physiology of Cells. The 2.5-day workshop included presentations from 20 expert speakers, poster sessions, networking discussions, and breakout sessions which identified key findings and provided recommendations to advance these technologies. Here, we will report on the proceedings, recommendations, and outcome of the April 2016 technical workshop, including paths forward for developing and validating non-animal test methods for tobacco product smoke and next generation tobacco product aerosol/vapour exposures. With the recent FDA publication of the final deeming rule for the governance of tobacco products, there is an unprecedented necessity to evaluate a very large number of tobacco-based products and ingredients. The questionable relevance, high cost, and ethical considerations for the use of in vivo testing methods highlight the necessity of robust in vitro approaches to elucidate tobacco-based exposures and how they may lead to pulmonary diseases that contribute to lung exposure-induced mortality worldwide.",
keywords = "Computational fluid dynamics, COPD, Dosimetry, E-cigarette exposure systems, Ex vivo lung models, In vitro, In vitro lung, In vitro models, Non-animal alternatives, Pulmonary models, Reconstructed epithelium airway models, Tobacco exposure systems, Tobacco regulatory science",
author = "Holger Behrsing and Erin Hill and Hans Raabe and Raymond Tice and Suzanne Fitzpatrick and Robert Devlin and Pinkerton, {Kent E} and G{\"u}nter Oberd{\"o}rster and Chris Wright and Roman Wieczorek and Michaela Aufderheide and Sandro Steiner and Tobias Krebs and Bahman Asgharian and Richard Corley and Michael Oldham and Jason Adamson and Xiang Li and Irfan Rahman and Sonia Grego and Chu, {Pei Hsuan} and Shaun McCullough and Rodger Curren",
year = "2017",
month = "7",
day = "1",
language = "English (US)",
volume = "45",
pages = "117--158",
journal = "ATLA Alternatives to Laboratory Animals",
issn = "0261-1929",
publisher = "FRAME",
number = "3",

}

TY - JOUR

T1 - In vitro exposure systems and dosimetry assessment tools for inhaled tobacco products

T2 - Workshop proceedings, conclusions and paths forward for in vitro model use

AU - Behrsing, Holger

AU - Hill, Erin

AU - Raabe, Hans

AU - Tice, Raymond

AU - Fitzpatrick, Suzanne

AU - Devlin, Robert

AU - Pinkerton, Kent E

AU - Oberdörster, Günter

AU - Wright, Chris

AU - Wieczorek, Roman

AU - Aufderheide, Michaela

AU - Steiner, Sandro

AU - Krebs, Tobias

AU - Asgharian, Bahman

AU - Corley, Richard

AU - Oldham, Michael

AU - Adamson, Jason

AU - Li, Xiang

AU - Rahman, Irfan

AU - Grego, Sonia

AU - Chu, Pei Hsuan

AU - McCullough, Shaun

AU - Curren, Rodger

PY - 2017/7/1

Y1 - 2017/7/1

N2 - In 2009, the passing of the Family Smoking Prevention and Tobacco Control Act facilitated the establishment of the FDA Center for Tobacco Products (CTP), and gave it regulatory authority over the marketing, manufacture and distribution of tobacco products, including those termed 'modified risk'. On 4-6 April 2016, the Institute for In Vitro Sciences, Inc. (IIVS) convened a workshop conference entitled, In Vitro Exposure Systems and Dosimetry Assessment Tools for Inhaled Tobacco Products, to bring together stakeholders representing regulatory agencies, academia and industry to address the research priorities articulated by the FDA CTP. Specific topics were covered to assess the status of current in vitro smoke and aerosol/vapour exposure systems, as well as the various approaches and challenges to quantifying the complex exposures in in vitro pulmonary models developed for evaluating adverse pulmonary events resulting from tobacco product exposures. The four core topics covered were: a) Tobacco Smoke and ECigarette Aerosols; b) Air-Liquid Interface-In Vitro Exposure Systems; c) Dosimetry Approaches for Particles and Vapours/In Vitro Dosimetry Determinations; and d) Exposure Microenvironment/Physiology of Cells. The 2.5-day workshop included presentations from 20 expert speakers, poster sessions, networking discussions, and breakout sessions which identified key findings and provided recommendations to advance these technologies. Here, we will report on the proceedings, recommendations, and outcome of the April 2016 technical workshop, including paths forward for developing and validating non-animal test methods for tobacco product smoke and next generation tobacco product aerosol/vapour exposures. With the recent FDA publication of the final deeming rule for the governance of tobacco products, there is an unprecedented necessity to evaluate a very large number of tobacco-based products and ingredients. The questionable relevance, high cost, and ethical considerations for the use of in vivo testing methods highlight the necessity of robust in vitro approaches to elucidate tobacco-based exposures and how they may lead to pulmonary diseases that contribute to lung exposure-induced mortality worldwide.

AB - In 2009, the passing of the Family Smoking Prevention and Tobacco Control Act facilitated the establishment of the FDA Center for Tobacco Products (CTP), and gave it regulatory authority over the marketing, manufacture and distribution of tobacco products, including those termed 'modified risk'. On 4-6 April 2016, the Institute for In Vitro Sciences, Inc. (IIVS) convened a workshop conference entitled, In Vitro Exposure Systems and Dosimetry Assessment Tools for Inhaled Tobacco Products, to bring together stakeholders representing regulatory agencies, academia and industry to address the research priorities articulated by the FDA CTP. Specific topics were covered to assess the status of current in vitro smoke and aerosol/vapour exposure systems, as well as the various approaches and challenges to quantifying the complex exposures in in vitro pulmonary models developed for evaluating adverse pulmonary events resulting from tobacco product exposures. The four core topics covered were: a) Tobacco Smoke and ECigarette Aerosols; b) Air-Liquid Interface-In Vitro Exposure Systems; c) Dosimetry Approaches for Particles and Vapours/In Vitro Dosimetry Determinations; and d) Exposure Microenvironment/Physiology of Cells. The 2.5-day workshop included presentations from 20 expert speakers, poster sessions, networking discussions, and breakout sessions which identified key findings and provided recommendations to advance these technologies. Here, we will report on the proceedings, recommendations, and outcome of the April 2016 technical workshop, including paths forward for developing and validating non-animal test methods for tobacco product smoke and next generation tobacco product aerosol/vapour exposures. With the recent FDA publication of the final deeming rule for the governance of tobacco products, there is an unprecedented necessity to evaluate a very large number of tobacco-based products and ingredients. The questionable relevance, high cost, and ethical considerations for the use of in vivo testing methods highlight the necessity of robust in vitro approaches to elucidate tobacco-based exposures and how they may lead to pulmonary diseases that contribute to lung exposure-induced mortality worldwide.

KW - Computational fluid dynamics

KW - COPD

KW - Dosimetry

KW - E-cigarette exposure systems

KW - Ex vivo lung models

KW - In vitro

KW - In vitro lung

KW - In vitro models

KW - Non-animal alternatives

KW - Pulmonary models

KW - Reconstructed epithelium airway models

KW - Tobacco exposure systems

KW - Tobacco regulatory science

UR - http://www.scopus.com/inward/record.url?scp=85027973751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027973751&partnerID=8YFLogxK

M3 - Article

C2 - 28816053

AN - SCOPUS:85027973751

VL - 45

SP - 117

EP - 158

JO - ATLA Alternatives to Laboratory Animals

JF - ATLA Alternatives to Laboratory Animals

SN - 0261-1929

IS - 3

ER -